Goldman raised the price target for the Ascendis Pharma A/S (NASDAQ:ASND) stock to “a Buy”. The rating was released on October 20, 2022, according to finviz. The research report from Wedbush has resumed the stock to Outperform, with a price target set at $163. The stock was upgraded by BofA Securities, who disclosed in a research note on March 15, 2022, from Neutral to Buy and set the price objective to $161. In their research brief published March 01, 2022, Citigroup analysts initiated the Ascendis Pharma A/S stock to Buy with a price target of $187.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Ascendis Pharma A/S (NASDAQ:ASND) dipped -1.04% to close Wednesday’s market session at $118.84, lower as compared to yesterday’s close. The stock price fluctuated between $116.07 and $122.80 throughout the trading session with the volume trading being 461100 shares, which represented a significant variation when compared to the three months average volume of 466.41K shares. The firm’s stock price fluctuated 3.47% within the last five trades and 11.17% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 31.61% in the last 6 months and 26.55% was added to its value over the previous 3 months. ASND stock is trading at a margin of 1.63%, 6.93% and 17.04% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
As of the close of trading, ASND deals in the Healthcare domain. The stock is trading -20.13 percent below its 52-week high and 92.99 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -4.7. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Ascendis Pharma A/S’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $6.60 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 191.94 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 14.18, which equates the market value of a stock with its book value.